"We are honored to welcome Dr. Long to Diamyd Medical's SAB," says Dr. Mark Atkinson, Chairman of Diamyd Medical's Scientific Advisory Board and Board member of Diamyd Medical. "Her landmark research around precision medicine and translation research for Type 1 Diabetes is fully aligned with the targeted approach of Diamyd^®. Her support will be vital in shaping the scientific awareness and positioning our therapy."

Dr. Alice Long is an Associate Member and Principal Investigator at the Center for Translational Immunology at Benaroya Research Institute. Dr. Long's translational immunology lab investigates the mechanisms behind the loss of immune tolerance in autoimmune diseases and explores therapeutic strategies to restore it. Her research spans three interconnected areas: understanding the diminished IL-2 response in autoimmune patients, defining the function and stability of CD8 T cell exhaustion linked to favorable outcomes in autoimmunity, and uncovering factors that influence differential responses to therapy among patients.

"I am excited to join Diamyd Medical in its mission to transform care for individuals with Type 1 Diabetes," says Alice Long. "The company's focus on innovative therapies and precision medicine resonates deeply with my research goals. I look forward to collaborating with the team to advance groundbreaking treatments that improve patient outcomes and redefine the possibilities for managing autoimmune diseases."

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd^® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. Diamyd^® has been granted Orphan Drug Designation in the U.S. as well as Breakthrough Designation and Fast Track Designation by the U.S. FDA for the treatment of Stage 3 Type 1 Diabetes. Diamyd^® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company's prospective European Phase IIb trial, where Diamyd^® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymph node can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB. Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.